In these 101 reports of patients with severe myocarditis after treatment with ICIs, most patients (57%) received anti-PD-1 monotherapy, while 27% of patients received anti-PD-1/PD-L1 plus anti-CTLA-4 combination therapy. The gene discussed is PDCD1; the disease is myocarditis.